Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 2,764,492	$ 2,058,980
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization	444,100	530,508
Share-based compensation	131,537	119,508
Deferred income taxes	(185,802)	(229,273)
Other	31,564	(95,711)
Changes in operating assets and liabilities, net:
Accounts receivable	(63,608)	(297,057)
Inventory	(150,387)	(119,890)
Accrued expenses and other current liabilities	(174,532)	19,283
Other changes in operating assets and liabilities, net	(121,659)	22,904
Net cash flows provided by operating activities	2,675,705	2,009,252
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	3,363,374	1,942,871
Purchases of marketable securities	(4,870,142)	(2,738,584)
Acquisitions of business, net of cash acquired	(198,798)	0
Purchases of property, plant and equipment	(456,885)	(180,854)
Contingent consideration related to Fumapharm AG acquisition	550,000	175,000
Other	(33,620)	(13,131)
Net cash flows used in investing activities	(2,746,071)	(1,164,698)
Cash flows from financing activities:
Purchase of treasury stock	(2,998,190)	(359,981)
Proceeds from issuance of stock for share-based compensation arrangements	(45,509)	(44,960)
Proceeds from borrowings	5,930,936	0
Repayment of borrowings	(2,083)	(2,674)
Excess tax benefit from stock options	70,778	90,423
Other	(62,147)	(15,336)
Net cash flows provided by (used in) financing activities	2,984,803	(242,608)
Net increase in cash and cash equivalents	2,914,437	601,946
Effect of exchange rate changes on cash and cash equivalents	(30,358)	(18,227)
Cash and cash equivalents, beginning of the period	1,204,924	602,562
Cash and cash equivalents, end of the period	$ 4,089,003	$ 1,186,281